Summary
Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting nonmedical use of prescription pain relievers in 2015. Oxycodone ARIR is the first abuse-deterrent formulation of an IR opioid approved by the Food and Drug Administration and was developed to have similar relative bioavailability to IR oxycodone. Patients can be converted from IR oxycodone to the same dose and dosing regimen of Oxycodone ARIR. It has been demonstrated that when crushed and taken intranasally, Oxycodone ARIR has a 47% and a 23% reduction in mean maximum drug liking compared with crushed intranasal IR oxycodone and intact oral Oxycodone ARIR, respectively.
Register to download
Pharmacokinetic Characteristics of Intranasal Administration of Oxycodone ARIR
You may also be interested in:
White Paper
Human ADME Studies With Radiolabeled Compounds Phase I-IIa
Radiolabeled medication is widely used in the assessment of human ADME and also increasingly in assessing absolute bioavailability (BA). Conducting…
Fact Sheet
Pharmacogenomics in Pain Management
Pharmacogenomics in Pain Management. In the US alone there are an estimated 100 million adults suffering from chronic pain. Pharmacogenomics and…
resource
Opportunities in low-level radiocarbon microtracing: applications and new technology
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation,…